Primer extension based quantitative polymerase chain reaction reveals consistent differences in the methylation status of the MGMT promoter in diffusely infiltrating gliomas (WHO grade II-IV) of adults

Journal of Neuro-Oncology

Volumn 104, Issue 1, 2011, Pages 293-303

  Vassella, Erik ^a   Vajtai, Istvan ^a   Bandi, Nora ^a   Arnold, Marlene ^a   Kocher, Verena ^a   Mariani, Luigi ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Astrocytoma; Formalin fixed paraffin embedded tissue; Loss of heterozygosity 1p and 19q; MGMT promoter methylation; Oligodendroglioma

Indexed keywords

GENOMIC DNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ADULT; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER GROWTH; CHROMOSOME 1P; CHROMOSOME ARM; CONTROLLED STUDY; DIFFUSELY INFILTRATING GLIOMA; DNA METHYLATION; FEMALE; GENE; GLIOBLASTOMA; GLIOMA; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOLECULAR CLONING; O6 METHYLGUANINE DNA METHYLTRANSFERASE GENE; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SENSITIVITY ANALYSIS; TISSUE FIXATION; TISSUE SPECIFICITY; VALIDATION PROCESS;

ADULT; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DNA METHYLATION; FEMALE; GLIOMA; HUMANS; LINEAR MODELS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; REPRODUCIBILITY OF RESULTS; STATISTICS AS TOPIC;

EID: 80052738668     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0490-4     Document Type: Article

References (40)

1. D Louis H Ohgaki O Wiestler W Cavenee P Burger A Jouvet B Scheithauer P Kleihues 2007 The 2007 WHO classification of tumours of the central nervous system Acta Neuropathol 114 97 109 17618441 10.1007/s00401-007-0243-4 (Pubitemid 47103521)
2. MJ van den Bent ME Hegi R Stupp 2006 Recent developments in the use of chemotherapy in brain tumours Eur J Cancer 42 582 588 16427778 10.1016/j.ejca.2005.06.031 (Pubitemid 43343679)
3. G Reifenberger DN Louis 2003 Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology J Neuropathol Exp Neurol 62 111 126 12578221 1:CAS:528:DC%2BD3sXhsFaiurs%3D (Pubitemid 36176946)
4. JS Smith A Perry TJ Borell H Lee J O'Fallon S Hosek D Kimmel A Yates P Burger B Scheithauer R Jenkins 2000 Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas and mixed oligoastrocytomas J Clin Oncol 18 636 645 10653879 1:STN:280: DC%2BD3c7itVyrsA%3D%3D (Pubitemid 30078545)
5. B Thiessen J Maguire K McNeil D Huntsman MA Martin D Horsman 2003 Loss of heterozygosity for loci on chromosome arms 1p and 19q in oligodendroglioma tumours: relationship to outcome and chemosensitivity J Neurooncol 64 271 278 14558604 10.1023/A:1025689004046 (Pubitemid 37203469)
6. M Kujas J Lejeune A Benouaich-Amiel E Crinière F Laigle-Donadey Y Marie K Mokhtari M Polivka M Bernier F Chretien A Couvelard L Capelle H Duffau P Cornu P Broët J Thillet A Carpentier M Sanson K Hoang-Xuan J Delattre 2005 Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas Ann Neurol 58 322 326 16049942 10.1002/ana.20543 1:CAS:528:DC%2BD2MXps1Cnsrw%3D (Pubitemid 41098891)
7. R Jenkins H Blair KV Ballman C Giannini R Arusell M Law H Flynn S Passe S Felten P Brown E Shaw J Buckner 2006 A t(1;19)(q10;p10) translocation mediates the combined deletions of 1p and 19q and predicts better prognosis of patients with oligodendroglioma Cancer Res 66 9852 9861 17047046 10.1158/0008-5472.CAN- 06-1796 1:CAS:528:DC%2BD28XhtVyiur3I (Pubitemid 44672036)
8. C Griffin P Burger L Morsberger R Yonescu S Swierczyknski JD Weingart K Murphy 2006 Identification of der (1;19)(q10;p10) in five oligodendrogliomas suggests a mechanism of concurrent 1p and 19q loss J Neuropathol Exp Neurol 65 988 994 17021403 10.1097/01.jnen.0000235122.98052.8f (Pubitemid 44521799)
9. K Hoang-Xuan L Capelle M Kujas S Taillibert H Duffau J Lejeune M Polivka E Crinière Y Marie K Mokhtari A Carpentier F Laigle J Simon P Cornu P Broët M Sanson J Delattre 2004 Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions J Clin Oncol 22 3133 3138 15284265 10.1200/JCO.2004.10. 169 1:CAS:528:DC%2BD2cXpsVGrs7o%3D (Pubitemid 41103727)
10. L Mariani G Deiana E Vassella AR Fathi C Murtin M Arnold I Vajtai J Weis P Siegenthaler M Schobesberger M Reinert 2006 Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy J Clin Oncol 24 4758 4763 16966689 10.1200/JCO.2006.05.9238 1:CAS:528:DC%2BD28XhtFynsrrM (Pubitemid 46630940)
11. ME Hegi A Murat WL Lambiv R Stupp 2006 Brain tumors: molecular biology and targeted therapies Ann Oncol 17 191 197 10.1093/annonc/mdl259 (Pubitemid 44542008)
12. M Esteller J Garcia-Foncillas E Andion SN Goodman OF Hidalgo V Vanaclocha SB Baylin JG Herman 2000 Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N Engl J Med 343 1350 1354 11070098 10.1056/NEJM200011093431901 1:CAS:528:DC%2BD3cXosFOltLg%3D
13. ME Hegi AC Diserens S Godard PY Dietrich L Regli S Ostermann P Otten G Van Melle N de Tribolet R Stupp 2004 Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide Clin Cancer Res 10 1871 1874 15041700 10.1158/1078-0432.CCR-03-0384 1:CAS:528:DC%2BD2cXisVGltbY%3D (Pubitemid 38375541)
14. ME Hegi A-C Diserens T Gorlia M Hamou N de Tribolet M Weller J Kros J Hainfellner W Mason L Mariani J Bromberg P Hau R Mirimanoff J Cairncross RRS Janzer 2005 MGMT gene silencing and benefit from Temozolomide in glioblastoma N Engl J Med 352 997 1003 15758010 10.1056/NEJMoa043331 1:CAS:528: DC%2BD2MXit1Wktro%3D (Pubitemid 40349502)
15. R Martinez G Schackert R Yaya-Tur I Rojas-Marcos JG Herman M Esteller 2007 Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme J Neurooncol 83 91 93 17164975 10.1007/s11060-006-9292-0 1:CAS:528:DC%2BD2sXmtVCqs7s%3D (Pubitemid 46647170)
16. R Stupp ME Hegi MR Gilbert A Chakravarti 2007 Chemoradiotherapy in malignant glioma: standard of care and future directions J Clin Oncol 25 4127 4136 17827463 10.1200/JCO.2007.11.8554 1:CAS:528:DC%2BD2sXhtlKqsbrE (Pubitemid 47492957)
17. PW Laird 2003 The power and the promise of DNA methylation markers Nat Rev Cancer 253 253 266 10.1038/nrc1045 (Pubitemid 37328861)
18. L Karayan-Tapon V Quillien J Guihot M Wager G Fromont S Saikali A Etcheverry A Hamlat D Loussouarn L Champion M Campone F-M Vallette C Gratas-Rabbia-Re 2010 Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods J Neurooncol 97 311 322 19841865 10.1007/s11060-009-0031-1 1:CAS:528: DC%2BC3cXltFOnsLw%3D
19. R Stupp ME Hegi WP Mason MJ van den Bent MJ Taphoorn RC Janzer SK Ludwin A Allgeier B Fisher K Belanger P Hau AA Brandes J Gijtenbeek C Marosi CJ Vecht K Mokhtari P Wesseling S Villa E Eisenhauer T Gorlia M Weller D Lacombe JG Cairncross RO Mirimanoff 2009 Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 459 466 19269895 10.1016/S1470-2045(09)70025-7 1:CAS:528: DC%2BD1MXlsVKhs74%3D
20. M Cankovic T Mikkelsen ML Rosenblum RJ Zarbo 2007 A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue Lab Invest 87 392 397 17260000 1:CAS:528:DC%2BD2sXjtlWgsLg%3D (Pubitemid 46474563)
21. I Vlassenbroeck S Califice AC Diserens E Migliavacca J Straub I Di Stefano F Moreau MF Hamou I Renard M Delorenzi B Flamion J DiGuiseppi K Bierau ME Hegi 2008 Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma J Mol Diagn 10 332 337 18556773 10.2353/jmoldx.2008.070169 1:CAS:528: DC%2BD1cXpt1eitr8%3D (Pubitemid 352019119)
22. D Nancarrow H HY M Stark D Whiteman H NK 2007 SiDCoN: a tool to aid scoring of DNA copy number changes in SNP chip data PLoS One 2 e1093 17971856 10.1371/journal.pone.0001093 (Pubitemid 351566685)
23. JG Herman JR Graff S Myohanen BD Nelkin SB Baylin 1996 Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands Proc Natl Acad Sci USA 93 9821 9826 8790415 10.1073/pnas.93.18.9821 1:CAS:528:DyaK28XlsFeht7Y%3D (Pubitemid 26296693)
24. T Mikeska C Bock O El-Maarri A Hubner D Ehrentraut J Schramm J Felsberg P Kahl R Buttner T Pietsch A Waha 2007 Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis J Mol Diagn 9 368 381 17591937 10.2353/jmoldx.2007.060167 1:CAS:528:DC%2BD2sXot1Kqsrc%3D (Pubitemid 47305073)
25. K Hattermann HM Mehdorn R Mentlein S Schultka J Held-Feindt 2008 A methylation-specific and SYBR-green-based quantitative polymerase chain reaction technique for O6-methylguanine DNA methyltransferase promoter methylation analysis Anal Biochem 377 62 71 18384736 10.1016/j.ab.2008.03.014 1:CAS:528:DC%2BD1cXlsFCmt70%3D
26. ML Gonzalgo PA Jones 2002 Quantitative methylation analysis using methylation-sensitive single-nucleotide primer extension (Ms-SNuPE) Methods 27 128 133 12095270 10.1016/S1046-2023(02)00064-6 1:CAS:528:DC%2BD38XltVShsbY%3D (Pubitemid 34757123)
27. JW Jeuken SJ Cornelissen M Vriezen MM Dekkers A Errami A Sijben SH Boots-Sprenger P Wesseling 2007 MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas Lab Invest 87 1055 1065 17700563 10.1038/labinvest.3700664 1:CAS:528:DC%2BD2sXhtVCrtLjF (Pubitemid 47429190)
28. M Mollemann M Wolter J Felsberg VP Collins G Reifenberger 2005 Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors Int J Cancer 113 379 385 15455350 10.1002/ijc.20575 (Pubitemid 40038704)
29. BC Christensen EA Houseman CJ Marsit S Zheng MR Wrensch JL Wiemels HH Nelson MR Karagas JF Padbury R Bueno DJ Sugarbaker RF Yeh JK Wiencke KT Kelsey 2009 Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context PLoS Genet 5 e1000602 19680444 10.1371/journal.pgen.1000602
30. MF Fraga R Agrelo M Esteller 2007 Cross-talk between aging and cancer: the epigenetic language Ann NY Acad Sci 1100 60 74 17460165 10.1196/annals.1395. 005 1:CAS:528:DC%2BD2sXlslOisLY%3D (Pubitemid 47092639)
31. P Parrella A la Torre M Copetti VM Valori R Barbano A Notarangelo M Bisceglia AP Gallo T Balsamo ML Poeta M Carella D Catapano S Parisi B Dallapiccola E Maiello V D'Angelo VM Fazio 2009 High specificity of quantitative methylation-specific PCR analysis for MGMT promoter hypermethylation detection in gliomas J Biomed Biotechnol 2009 531692 19503806 10.1155/2009/531692
32. M Preusser 2009 MGMT analysis at DNA, RNA and protein levels in glioblastoma tissue Histol Histopathol 24 511 518 19224454 1:CAS:528: DC%2BD1MXltFCntrg%3D
33. M Weller R Stupp G Reifenberger AA Brandes MJ van den Bent W Wick ME Hegi 2010 MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6 39 51 19997073 10.1038/nrneurol.2009.197 1:CAS:528:DC%2BC3cXisV2gtA%3D%3D
34. J Dunn A Baborie F Alam K Joyce M Moxham R Sibson D Crooks D Husband A Shenoy A Brodbelt H Wong T Liloglou B Haylock C Walker 2009 Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy Br J Cancer 101 124 131 19536096 10.1038/sj.bjc.6605127 1:CAS:528:DC%2BD1MXotVKgtLk%3D
35. L Juillerat-Jeanneret CC Bernasconi C Bricod S Gros S Trepey J Benhattar RC Janzer 2008 Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase Cancer Invest 26 597 609 18584351 10.1080/07357900802072913 1:CAS:528:DC%2BD1cXnsl2rtL4%3D (Pubitemid 351918586)
36. JF Parkinson HR Wheeler A Clarkson CA McKenzie MT Biggs NS Little RJ Cook M Messina BG Robinson KL McDonald 2008 Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma J Neurooncol 87 71 78 18004504 10.1007/s11060-007-9486-0 1:CAS:528: DC%2BD1cXivFygtro%3D
37. EM Grasbon-Frodl FW Kreth M Ruiter O Schnell K Bise J Felsberg G Reifenberger JC Tonn HA Kretzschmar 2007 Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas Int J Cancer 121 2458 2464 17691113 10.1002/ijc.23020 1:CAS:528:DC%2BD2sXhtlShtbzM (Pubitemid 350022415)
38. Ochsenbein AF, Schubert AD, Vassella E, Mariani L (2010) Quantitative analysis of O(6)-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas. J Neurooncol [Epub ahead of print]
39. MJ van den Bent HJ Dubbink M Sanson CR van der Lee-Haarloo M Hegi JW Jeuken A Ibdaih AA Brandes MJ Taphoorn M Frenay D Lacombe T Gorlia WN Dinjens JM Kros 2009 MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951 J Clin Oncol 27 5881 5886 19901104 10.1200/JCO.2009.24.1034
40. W Wick C Hartmann C Engel M Stoffels J Felsberg F Stockhammer MC Sabel S Koeppen R Ketter R Meyermann M Rapp C Meisner RD Kortmann T Pietsch OD Wiestler U Ernemann M Bamberg G Reifenberger A von Deimling M Weller 2009 NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide J Clin Oncol 27 5874 5880 19901110 10.1200/JCO.2009.23.6497 1:CAS:528:DC%2BC3cXhtVWis7g%3D